1,3,5,6-tetrahydroxyxanthone promotes diuresis, renal protection and antiurolithic properties in normotensive and hypertensive rats.


Journal

The Journal of pharmacy and pharmacology
ISSN: 2042-7158
Titre abrégé: J Pharm Pharmacol
Pays: England
ID NLM: 0376363

Informations de publication

Date de publication:
27 Mar 2021
Historique:
received: 28 09 2020
accepted: 29 01 2021
entrez: 27 3 2021
pubmed: 28 3 2021
medline: 9 11 2021
Statut: ppublish

Résumé

This study investigated the prolonged diuretic and renal effects of 1,3,5,6- tetrahydroxyxanthone (THX) in rats. Normotensive (NTR) and hypertensive rats (SHR) received orally the treatment with THX, hydrochlorothiazide or vehicle (VEH). Urine volume, urinary, plasma and kidney parameters were evaluated daily or at the end of 7 days of the experiment. The urinary volume of both NTR and SHR were significantly augmented with the THX treatment, an effect associated with increased levels of urinary Na+ and K+, besides a Ca2+-sparing effect. As well, THX decreased the quantity of monohydrate crystals in urines from NTR and SHR when compared with VEH-group. Regarding the renal analyses, the glutathione levels and the activities of superoxide dismutase, glutathione S-transferase and myeloperoxidase in kidney homogenates of the SHR group were decreased. In contrast, the generation of lipid hydroperoxides (LOOH) and catalase activity was significantly increased. THX reduced the content of LOOH and increased nitrite levels in kidney homogenates obtained from SHR. Additionally, THX also augmented the levels of nitrite in the plasma from the SHR group. Therefore, THX can be highlighted as a natural diuretic agent with renal protective properties and antiurolithic action.

Identifiants

pubmed: 33772292
pii: 6154867
doi: 10.1093/jpp/rgab026
doi:

Substances chimiques

1,3,5,6-tetrahydroxyxanthone 0
Diuretics 0
Xanthones 0
Nitric Oxide 31C4KY9ESH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-708

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Luísa Nathália Bolda Mariano (LNB)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Thaise Boeing (T)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Valdir Cechinel Filho (V)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Rivaldo Niero (R)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Luisa Mota da Silva (L)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Priscila de Souza (P)

Postgraduate Program in Pharmaceutical Sciences, Nucleus of Chemical-Pharmaceutical Investigations, University of Vale do Itajaí (UNIVALI), Itajaí, Brazil.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH